{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-004785","form_type":"8-K","ticker":"NVAX","cik":"0001000694","company_name":"NOVAVAX INC","filed_at":"2026-01-20T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.364896+00:00","generated_at":"2026-05-16T09:27:30.682618+00:00","sec_items":["1.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Novavax licenses Matrix-M adjuvant to Pfizer for up to $500M milestones plus royalties","bullets":["Upfront payment of $30M in Q1 2026; eligible for up to $500M in milestones ($70M development, $180M sales per field).","Tiered high mid-single digit royalties on net sales until later of 20 years or patent expiry.","Non-exclusive worldwide license for up to two infectious disease fields; first field selected, second at Pfizer's option.","Pfizer controls development, manufacturing, and commercialization; separate supply agreements to be finalized."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-004785","json":"https://secwatch.observer/filing/0001104659-26-004785.json","markdown":"https://secwatch.observer/filing/0001104659-26-004785.md","text":"https://secwatch.observer/filing/0001104659-26-004785.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1000694/000110465926004785/0001104659-26-004785-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1000694/000110465926004785/tm263587d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T09:27:30.682618+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"166a4da24dccc48a2bcff738fdd79434b931f801","claim":"NOVAVAX INC entered into License and Option Agreement with Pfizer Inc. valued at $30 million (effective 2026-01-15).","evidence_excerpt":"On January 15, 2026, (the “Effective Date”), Novavax, Inc. (the “Company”) entered into a License and Option Agreement (the “License and Option Agreement”) with Pfizer Inc. (“Pfizer”)","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1000694/000110465926004785/0001104659-26-004785-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"Pfizer Inc."},{"label":"Value","value":"$30 million"},{"label":"Effective","value":"2026-01-15"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}